Filing Details

Accession Number:
0001062993-22-018390
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-18 17:10:22
Reporting Period:
2022-08-16
Accepted Time:
2022-08-18 17:10:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1805387 Cerevel Therapeutics Holdings Inc. CERE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1164426 Joseph Edelman 51 Astor Place, 10Th Floor
New York NY 10003
Yes No No No
1224962 Perceptive Advisors Llc 51 Astor Place, 10Th Floor
New York NY 10003
Yes No No No
1249675 Ltd Fund Master Sciences Life Perceptive 51 Astor Place, 10Th Floor
New York NY 10003
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-16 1,425,000 $35.00 6,511,727 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock 2.50% Convertible Senior Notes Due 2027 Acquisiton 2022-08-16 0 $100,000,000.00 2,156,102 $46.38
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2027-08-15 No 4 P Indirect
Footnotes
  1. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Mr. Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
  2. Before May 15, 2027, holders of the 2.50% Convertible Senior Notes Due 2027 (the "Notes") have the right to convert their Notes to shares of the Issuer's common stock only upon the occurrence of certain events specified in the indenture, dated August 16, 2022, setting forth the terms of the Notes. From and after May 15, 2027, holders of the Notes may convert their Notes to common stock at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date of the Notes.